Legacy Wealth Asset Management LLC Sells 40 Shares of argenx SE (NASDAQ:ARGX)

Legacy Wealth Asset Management LLC cut its stake in shares of argenx SE (NASDAQ:ARGX) by 2.9% in the fourth quarter, Holdings Channel reports. The firm owned 1,360 shares of the company’s stock after selling 40 shares during the quarter. Legacy Wealth Asset Management LLC’s holdings in argenx were worth $836,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Profund Advisors LLC grew its position in shares of argenx by 3.0% during the 2nd quarter. Profund Advisors LLC now owns 973 shares of the company’s stock worth $418,000 after buying an additional 28 shares during the period. Raymond James Trust N.A. boosted its stake in argenx by 6.0% during the 3rd quarter. Raymond James Trust N.A. now owns 495 shares of the company’s stock worth $268,000 after acquiring an additional 28 shares during the last quarter. Wealth Alliance grew its holdings in argenx by 4.8% during the second quarter. Wealth Alliance now owns 628 shares of the company’s stock valued at $270,000 after purchasing an additional 29 shares during the period. Hantz Financial Services Inc. increased its stake in argenx by 8.9% in the third quarter. Hantz Financial Services Inc. now owns 528 shares of the company’s stock valued at $286,000 after purchasing an additional 43 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in argenx by 47.5% in the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock valued at $94,000 after purchasing an additional 56 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx Trading Down 0.8 %

NASDAQ:ARGX opened at $659.81 on Friday. The stock has a market capitalization of $39.83 billion, a PE ratio of -749.78 and a beta of 0.59. argenx SE has a 1-year low of $349.86 and a 1-year high of $678.21. The firm has a fifty day simple moving average of $619.30 and a 200 day simple moving average of $554.23.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, October 31st. The company reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. The company had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same quarter last year, the firm posted ($1.25) EPS. On average, equities analysts predict that argenx SE will post 2.17 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ARGX has been the topic of a number of recent analyst reports. Guggenheim lifted their price target on shares of argenx from $585.00 to $665.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. William Blair upgraded argenx from a “market perform” rating to an “outperform” rating in a report on Friday, November 1st. Piper Sandler increased their price target on argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a report on Tuesday, January 7th. JMP Securities lifted their price objective on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a report on Tuesday. Finally, HC Wainwright reissued a “buy” rating and set a $717.00 target price (up from $670.00) on shares of argenx in a research note on Tuesday. Three analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $658.39.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.